A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Fortrea.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
202actual
Sites
26
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-30 | actual | When the study began enrolling |
| Primary completion | 2025-04-18 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-02 | actual | The whole study's end, after follow-up |
| First posted | 2024-11-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Atherosclerotic Cardiovascular Disease
Interventions
- Drug: Placebo
- Drug: AZD0780
Primary outcome
what the primary-completion date above is the date OFTo assess the effect of treatment with AZD0780 dose 1 versus placebo on ambulatory 24-hour average SBP at Week 4
measured Week 4
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed